Technology | 2009.11.02
NOXXON Announces Initiation of First-in-Human Clinical Trial with Hematopoietic Stem Cell Mobilizing Spiegelmer® NOX-A12
BERLIN--(BUSINESS WIRE)--NOXXON Pharma AG, the biopharmaceutical company focusing on the development of novel drugs based on its unique proprietary Spiegelmer® technology, announced today the successful initial dosing of healthy volunteers in a first-in-human clinical trial with Spiegelmer® NOX-A12. NOX-A12 is NOXXON’s second drug candidate entering the clinical stage of development within only five months. The Phase I program is currently being conducted in Germany following rev
For more information, please visit
http://www.businesswire.com/news/home/20091102005517/en
